上海貝嶺(600171.SH):已逐步形成了若干優勢產品
格隆匯12月5日丨有投資者向上海貝嶺(600171.SH)提問:這種業績説明會的意義在哪兒,一直是答非所問,讓投資者看公吿,不能正視、直視投資者的提問,説來説去還是那幾句話,請您看看董祕先生的回覆,就為了得獎才來辦的説明會嗎 ?貝嶺最近信息披露的獎吧?
上海貝嶺回覆:您好!因為公司過去研發投入不足,產品競爭力整體偏弱,未形成顯著的產品和市場優勢。近幾年公司持續加大研發投入,已逐步形成了若干優勢產品。我們後續將通過多種渠道,加強和機構投資者、中小投資者的交流溝通,積極宣傳公司的產品業務優勢,並繼續做好公司的市值管理工作。謝謝!
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.